Arbutus Biopharma (ABUS) Reports In-Line Q1 EPS

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• ADNOC Distribution agrees to buy Shell's South Africa unit for $1B